Black Diamond Therapeutics reports Q4 2023 net loss of $19.4M, ends year with $131.4M cash

Black Diamond Therapeutics, Inc.

Net loss Q4 2023 $19.4M vs $21.1M in Q4 2022; full year net loss $82.4M vs $91.2M.
Cash, cash equivalents, investments $131.4M at Dec 31, 2023; expected to fund operations into Q2 2025.
Dosed first patient in Phase 2 trial of BDTX-1535 in 1L non-classical EGFRm NSCLC; Phase 2 data expected Q3 2024.
GBM results for BDTX-1535 in Q2 2024, initial results for BDTX-4933 in KRASm NSCLC in Q4 2024.
R&D expenses decreased to $59.4M for FY2023 from $64.4M in FY2022, primarily due to reduced early discovery spend.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Black Diamond Therapeutics, Inc. reported the year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023 was $82.4 million.

Period: the year ended December 31, 2023
Net income: Net loss for the year ended December 31, 2023 was $82.4 million
Result: reported results

Exact text from the filing

Net loss for the year ended December 31, 2023 was $82.4 million compared to $91.2 million for the year ended December 31, 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Black Diamond Therapeutics, Inc. reported the fourth quarter ended December 31, 2023 results: net income Net loss for the fourth quarter of 2023 was $19.4 million.

Period: the fourth quarter ended December 31, 2023
Net income: Net loss for the fourth quarter of 2023 was $19.4 million
Result: reported results

Exact text from the filing

Net loss for the fourth quarter of 2023 was $19.4 million, as compared to $21.1 million for the same period in 2022.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Black Diamond Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001701541-24-000009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.